Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
May 12th, 2023
Here, we describe a method for transducing human T cells with luciferase to facilitate in vivo tracking of bispecific antibody-induced T cell trafficking to tumors in studies to evaluate the anti-tumor efficacy and mechanism of T cell-engaging bispecific antibodies.
Overview
This article describes a method for transducing human T cells with luciferase, enabling in vivo tracking of T cell trafficking to tumors. This technique is particularly useful for evaluating the anti-tumor efficacy of bispecific antibodies.
Key Study Components
Area of Science
- Immunology
- Oncology
- Cell Biology
Background
- Tracking T cells in vivo is crucial for understanding their behavior in tumor environments.
- Traditional methods often require animal sacrifice, limiting longitudinal studies.
- Luciferase transduction offers a non-invasive tracking method.
- This technique can potentially be adapted for other immune cell types.
Purpose of Study
- To develop a method for real-time tracking of T cells in vivo.
- To evaluate the kinetics of T cell homing to tumors.
- To monitor T cell persistence over time.
Methods Used
- Transduction of human T cells with luciferase.
- In vivo imaging to track T cell movement.
- Evaluation of bispecific antibody efficacy.
- Cell culture techniques for 293T cells.
Main Results
- The method allows repeated tracking of T cells without sacrificing the animal.
- Demonstrated effective monitoring of T cell trafficking to tumors.
- Potential for adaptation to other immune cell types.
- Facilitates understanding of T cell behavior in therapeutic contexts.
Conclusions
- This technique enhances the ability to study T cell dynamics in vivo.
- It provides insights into the mechanisms of bispecific antibody action.
- Future applications may extend to various immune cell types.
Frequently Asked Questions
Executive Industry Relevance
Quantitative tracking of T cell trafficking in vivo is a critical inflection point for bispecific antibody development, enabling direct assessment of immune cell homing and persistence in solid tumor models. This method provides predictive confidence for therapeutic efficacy by correlating T cell localization with anti-tumor outcomes, supporting risk-adjusted advancement decisions in immuno-oncology pipelines. The approach enhances translational continuity by allowing repeated, non-terminal measurements across treatment timelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct interrogation of T cell trafficking mechanisms in response to bispecific antibody formats.
- Supports functional target validation by linking antibody design features to in vivo T cell homing.
- Facilitates mechanistic de-risking by distinguishing between antibody variants based on trafficking kinetics.
Screening & Assay Development
- Provides a validated, quantitative readout for T cell infiltration and persistence in tumor xenografts.
- Enables reproducible, longitudinal assessment of immune cell dynamics without animal sacrifice.
- Supports assay standardization for comparing bispecific antibody candidates across studies.
Translational & Preclinical Research
- Aligns preclinical models with disease-relevant immune trafficking endpoints for solid tumors.
- Enables translational biomarker development by correlating in vivo imaging signals with therapeutic response.
- Supports risk-adjusted progression of candidates with superior trafficking and persistence profiles.
Pipeline & Workflow Integration
This method integrates into the immuno-oncology discovery continuum from early mechanistic studies through preclinical candidate selection, providing a reusable platform for evaluating T cell-engaging therapeutics.
- Discovery Biology: Quantifies T cell homing and persistence to clarify bispecific antibody mechanism of action.
- Screening: Delivers standardized, quantitative trafficking data for candidate triage.
- Analytics: Enables statistical comparison of trafficking kinetics and persistence across antibody formats and interventions.
- Translational Research: Bridges preclinical findings to clinical endpoints by modeling immune cell dynamics in vivo.
- Enterprise Reuse: Adaptable for tracking other immune cell types or therapeutic modalities in future studies.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in candidate selection by linking trafficking to efficacy.
- Operational Value: Reduces animal use and enables repeated, standardized measurements across cohorts.
- Strategic Value: Improves go/no-go decisions by providing mechanistic data on immune cell behavior.
- Portfolio Impact: Supports risk-adjusted prioritization of bispecific antibody formats with superior trafficking profiles.
Implementation Considerations
- Requires expertise in T cell culture, viral transduction, and in vivo imaging.
- Demands access to bioluminescence imaging infrastructure and analytical software.
- Standardization of imaging parameters is critical for cross-study comparability.
- Adaptation to other immune cell types may require protocol optimization.
- Signal quantitation may be influenced by tumor location and tissue depth.
Biopharma FAQs
Chapters in this video
0:04
Introduction
0:39
Transfection of 293T Cells with Luciferase and Harvest of Viral Supernatant
3:22
Expansion and Transduction of Activated Human T Cells with Luciferase
6:20
Engraftment of Luciferase‐Transduced T cells in Immunocompromised Mice and In Vivo Imaging
7:41
Results: Evaluating the Anti‐Tumor Efficacy and Mechanism of T Cell‐Engaging Bispecific Antibodies
9:51
Conclusion
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg%3Fv%3D2026-08-31T09%253A29%253A55.000Z&w=384&q=75)
